Abeona Therapeutics Inc SMA 200
Was ist das SMA 200 von Abeona Therapeutics Inc?
SMA 200 von Abeona Therapeutics Inc ist $6 +0.08%
Was ist die Definition von SMA 200?
SMA 200 ist ein durchschnittlicher Aktienkurs der letzten 200 Tage, berechnet als ungewichteter Mittelwert der letzten 200 Schlusskurse.
Simple moving average of 200 days for a stock is an unweighted moving average over the past 200 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 200 von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Abeona Therapeutics Inc
Was macht Abeona Therapeutics Inc?
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Unternehmen mit sma 200 ähnlich Abeona Therapeutics Inc
- Applied Dna Sciences Inc hat SMA 200 von $6 -269.28%
- Voya International High Dividend Equity Income Fund hat SMA 200 von $6 +0.00%
- MDC Partners hat SMA 200 von $6 -2.95%
- Riskified hat SMA 200 von $6 -21.88%
- Ferratum Oyj hat SMA 200 von €6 -12.67%
- Zevra Therapeutics Inc hat SMA 200 von $6 +3.90%
- Abeona Therapeutics Inc hat SMA 200 von $6 +0.08%
- Biodelivery Sciences International hat SMA 200 von $6 +0.00%
- Antares Pharma Inc hat SMA 200 von $6 +0.00%
- Chesswood hat SMA 200 von CAD$6 -521.14%
- Lantern Pharma hat SMA 200 von $6 -50.31%
- Nuveen Credit Strategies Income Fund hat SMA 200 von $6 +5.37%
- IMP Powers hat SMA 200 von ₨6 +0.00%